NQO1
Summary: This gene is a member of the NAD(P)H dehydrogenase (quinone) family and encodes a cytoplasmic 2-electron reductase. This FAD-binding protein forms homodimers and reduces quinones to hydroquinones. This protein's enzymatic activity prevents the one electron reduction of quinones that results in the production of radical species. Mutations in this gene have been associated with tardive dyskinesia (TD), an increased risk of hematotoxicity after exposure to benzene, and susceptibility to various forms of cancer. Altered expression of this protein has been seen in many tumors and is also associated with Alzheimer's disease (AD). Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jul 2008].
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| NAD(P)H quinone dehydrogenase 1 | MIM:125860 | Ensembl:ENSG00000181019 | HGNC:HGNC:2874 | PA31744 | 16q22.1 |
Gene Categories:
DRUGGABLE GENOMEGO terms in NQO1
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| MF | HDA | GO:0003723 | RNA binding |
| MF | IBA | GO:0003955 | NAD(P)H dehydrogenase (quinone) activity |
| MF | IEA | GO:0003955 | NAD(P)H dehydrogenase (quinone) activity |
| MF | TAS | GO:0004128 | cytochrome-b5 reductase activity, acting on NAD(P)H |
| MF | IEA | GO:0004784 | superoxide dismutase activity |
| MF | IPI | GO:0005515 | protein binding |
| MF | IBA | GO:0009055 | electron transfer activity |
| MF | IBA | GO:0016491 | oxidoreductase activity |
| MF | IPI | GO:0042802 | identical protein binding |
| BP | TAS | GO:0006521 | regulation of cellular amino acid metabolic process |
| BP | TAS | GO:0006805 | xenobiotic metabolic process |
| BP | TAS | GO:0006809 | nitric oxide biosynthetic process |
| BP | TAS | GO:0007271 | synaptic transmission, cholinergic |
| BP | IEA | GO:0007568 | aging |
| BP | IEA | GO:0007584 | response to nutrient |
| BP | TAS | GO:0009636 | response to toxic substance |
| BP | IEA | GO:0019430 | removal of superoxide radicals |
| BP | IEA | GO:0032355 | response to estradiol |
| BP | IEA | GO:0043066 | negative regulation of apoptotic process |
| BP | IEA | GO:0043086 | negative regulation of catalytic activity |
| BP | IEA | GO:0043525 | positive regulation of neuron apoptotic process |
| BP | IEA | GO:0045471 | response to ethanol |
| BP | IEA | GO:0051602 | response to electrical stimulus |
| BP | IEA | GO:0055114 | oxidation-reduction process |
| BP | IEA | GO:0070301 | cellular response to hydrogen peroxide |
| BP | IEA | GO:0071248 | cellular response to metal ion |
| BP | IEA | GO:1901698 | response to nitrogen compound |
| BP | IEA | GO:1904880 | response to hydrogen sulfide |
| CC | TAS | GO:0005737 | cytoplasm |
| CC | IBA | GO:0005829 | cytosol |
| CC | IDA | GO:0005829 | cytosol |
| CC | TAS | GO:0005829 | cytosol |
| CC | IEA | GO:0030425 | dendrite |
| CC | IEA | GO:0043025 | neuronal cell body |
Gene expression in normal tissue: NQO1
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in NQO1
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| pid | tap63pathway | Validated transcriptional targets of TAp63 isoforms |
| pharmgkb | PA145011115 | Phenytoin Pathway, Pharmacokinetics |
| pharmgkb | PA150642262 | Platinum Pathway, Pharmacokinetics/Pharmacodynamics |
| pharmgkb | PA165292163 | Doxorubicin Pathway (Cancer Cell), Pharmacodynamics |
| pharmgkb | PA165292177 | Doxorubicin Pathway, Pharmacokinetics |
| kegg | hsa00130 | Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human) |
| kegg | hsa05200 | Pathways in cancer - Homo sapiens (human) |
| kegg | hsa05225 | Hepatocellular carcinoma - Homo sapiens (human) |
| kegg | hsa05418 | Fluid shear stress and atherosclerosis - Homo sapiens (human) |
| wikipathways | WP2436 | Dopamine metabolism |
| wikipathways | WP2586 | Aryl Hydrocarbon Receptor |
| wikipathways | WP2864 | Apoptosis-related network due to altered Notch3 in ovarian cancer |
| wikipathways | WP2873 | Aryl Hydrocarbon Receptor Pathway |
| wikipathways | WP2882 | Nuclear Receptors Meta-Pathway |
| wikipathways | WP2884 | NRF2 pathway |
| wikipathways | WP3 | Transcriptional activation by NRF2 |
| wikipathways | WP3612 | Photodynamic therapy-induced NFE2L2 (NRF2) survival signaling |
| wikipathways | WP3670 | Simplified Interaction Map Between LOXL4 and Oxidative Stress Pathway |
| wikipathways | WP3891 | Benzene metabolism |
| wikipathways | WP408 | Oxidative Stress |
| wikipathways | WP697 | Estrogen metabolism |
| smpdb | SMP00327 | Phenytoin (Antiarrhythmic) Action Pathway |
| smpdb | SMP00464 | Vitamin K Metabolism |
| smpdb | SMP00650 | Doxorubicin Metabolism Pathway |
| reactome | R-HSA-1430728 | Metabolism |
| reactome | R-HSA-350562 | Regulation of ornithine decarboxylase (ODC) |
| reactome | R-HSA-351202 | Metabolism of polyamines |
| reactome | R-HSA-71291 | Metabolism of amino acids and derivatives |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD353 | PD0325901 | 2 |
| iGMDRD309 | 17AAG | 2 |
| iGMDRD236 | Amrubicin | 2 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in NQO1
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.